SynthesisJournal of prevention (2022)2024
Global Prevalence of Metabolic Syndrome in Schizophrenia Patients: A Systematic Review and Meta-Analysis.
Synthesis in Journal of prevention (2022), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- The role of anti-inflammatory diets and supplementation in metabolic syndrome and symptom remission in adults with schizophrenia: a systematic review.Frontiers in psychiatry · 2024Pooled it
- Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross-Sectional Study of 1553 Patients.Acta psychiatrica Scandinavica · 2026Observational
- Can Polygenic Risk Scores for Metabolic Syndrome Contribute to Long-Term Syndrome Development in First-Episode Psychosis Patients? A Naturalistic 21-Year Follow-Up Study.Schizophrenia bulletin · 2026Article
- Cross-population validation of European GWAS loci for metabolic syndrome in Chinese schizophrenia.BMC psychiatry · 2026Article
- Prevalence and Healthcare Costs of Metabolic Disorders Among Individuals with Schizophrenia Following Initiation of Oral Antipsychotic Therapy.PharmacoEconomics - open · 2026Article
- Association of metabolic syndrome with comorbid major depressive disorder in remitted schizophrenia: a cross-sectional study.BMC psychiatry · 2026Article
- Decreased concentration of transcription factor 21 in patients with chronic schizophrenia is associated with an increased coronary artery calcium score.BMC psychiatry · 2026Article
- Global prevalence of metabolic syndrome among individuals with sarcopenia: a systematic review and meta-analysis of 72,129 patients.Diabetology & metabolic syndrome · 2026Review
- Prevalence and risk profiles of metabolic abnormalities (PRIMA): a large-scale, multicenter cross-sectional study among inpatients with schizophrenia in China.BMC psychiatry · 2026Article
- The "5-4-3" model for weight management in psychiatric inpatients: a single-arm pre-post evaluation.Frontiers in public health · 2026Article
- Prevalence and associated factors of metabolic syndrome in patients with schizophrenia: a multicenter cross-sectional study in China.Schizophrenia (Heidelberg, Germany) · 2025Article
- A rare case of isovaleric acidemia and schizophrenia: a case report.BMC psychiatry · 2025Article
- The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).Molecular medicine reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of metabolic syndrome in patients with schizophrenia has significantly increased and can be associated with severe complications such as chronic diseases and mortality. Despite numerous studies, a comprehensive estimate of the prevalence of metabolic syndrome in schizophrenia patients is lacking. Therefore, this study aimed to estimate the global prevalence of metabolic syndrome in schizophrenia patients through a systematic review and meta-analysis. This study was conducted as a systematic review and meta-analysis based on PRISMA guidelines without time restrictions until April 1, 2024. Relevant articles were identified through searches in databases including Scopus, Web of Science (WoS), PubMed, Science Direct, Embase, and Google Scholar, using key terms combined with AND & OR operators. After removing duplicates and conducting primary and secondary screening, 12 studies were included in the meta-analysis. Data were analysed using the random-effects model in Comprehensive Meta-Analysis Version 2 software. This analysis included 12 studies with 1,953 participants. The pooled prevalence of metabolic syndrome was 41.3% (95% CI: 28.8-55.1), with significant heterogeneity (I
Indexed as
Identifiers
39048892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.